

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 13, 2007**

---

**HAPC, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**0-51902**  
(Commission File Number)

**20-3341405**  
(I.R.S. Employer  
Identification No.)

**350 Madison Avenue**  
**New York, New York 10017**  
(Address of Principal Executive Offices)(Zip Code)

**(212) 418-5070**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

---

**Item 8.01 Other Events**

On August 13, 2007, HAPC, INC., a Delaware corporation (“HAPC”) issued a press release announcing that it had filed with the U.S. Securities and Exchange Commission its definitive proxy statement relating to the previously announced acquisition of InfuSystem, Inc., a California corporation and wholly-owned subsidiary of I-Flow Corporation (“InfuSystem”). A special annual meeting of HAPC stockholders has been scheduled for Wednesday, September 26, 2007 at the offices of Morgan, Lewis & Bockius LLP, 101 Park Avenue, New York, 10178. HAPC stockholders of record as of August 6, 2007 will be eligible to vote at the special annual meeting. If the acquisition is approved, upon closing of the transaction, InfuSystem, will become wholly owned by HAPC, which will be renamed InfuSystem Holdings, Inc.

HAPC’s press release announcing the filing of its definitive proxy statement is attached hereto as Exhibit 99.1.

---

**Additional Information and Where to Find It**

In connection with the proposed acquisition and required stockholder approval, HAPC filed a definitive proxy statement with the U.S. Securities and Exchange Commission. HAPC commenced mailing the definitive proxy statement to its stockholders on August 8, 2007. HAPC's stockholders are urged to read the definitive proxy statement and other relevant materials as they contain important information about the acquisition of all of the issued and outstanding capital stock of InfuSystem. HAPC stockholders may obtain a free copy of such filings at the U.S. Securities and Exchange Commission's internet site (<http://www.sec.gov>). Copies of such filings can also be obtained, without charge, by directing a request to HAPC, INC., 350 Madison Avenue, New York, New York 10017, Tel: (212) 418-5070.

HAPC and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of HAPC in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the proposed transaction is included in the definitive proxy statement of HAPC described above.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release issued by HAPC, INC. on August 13, 2007

---

## **Forward Looking Statements**

This Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. These forward-looking statements include, but are not limited to, statements regarding whether the transaction will be completed and the expected timing of the closing. Readers are cautioned that these forward-looking statements involve certain risks and uncertainties. These risks and uncertainties, which could cause these forward-looking statements to not be realized, include delays in or failure to obtain necessary regulatory approvals or clearances or third-party consents for the parties to complete the acquisition, material changes in the business and financial condition of InfuSystem, increased competition in the markets in which InfuSystem competes, adverse changes in financial markets and the markets for InfuSystem’s products, unanticipated material adverse developments regarding InfuSystem such as new actual or contingent liabilities, litigation or the loss of key personnel, and the availability of companies to acquire on terms and conditions acceptable to HAPC. HAPC disclaims any obligation to update any information contained in any forward-looking statement.

---

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAPC, INC.

By: /s/ Erin Enright

Name: Erin Enright

Title: Chief Financial Officer

Dated: August 13, 2007

---

EXHIBIT LIST

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release issued by HAPC, INC. on August 13, 2007.

**HAPC, INC.****For Immediate Release****HAPC Sets September 26, 2007 as Date for Proxy Vote to Approve InfuSystem Acquisition Monday August 13, 8:49 am ET**

NEW YORK—(BUSINESS WIRE)—HAPC, Inc. (OTCBB: HAPN; HAPNW; HAPNU), today announced that it has filed with the Securities and Exchange Commission its definitive proxy statement relating to the previously announced acquisition of InfuSystem, Inc. A special meeting of HAPC stockholders has been scheduled for Wednesday, September 26, 2007 at the offices of Morgan, Lewis & Bockius LLP, 101 Park Avenue, New York, 10178. HAPC stockholders of record as of August 6, 2007 will be eligible to vote at the special annual meeting. If the acquisition is approved, upon closing of the transaction, InfuSystem, Inc. will become wholly owned by HAPC, which will be renamed InfuSystem Holdings, Inc.

“I am pleased to announce the filing and mailing of HAPC’s definitive proxy statement,” commented Sean McDevitt, Chairman of HAPC. “Since its inception, InfuSystem has grown into a \$31.7 million revenue company with a 32% compound annual growth rate in revenue since 2002. These results were achieved without the benefit of an aggressive marketing program. In addition, InfuSystem boasts an impressive 60% penetration of oncologist offices in the United States, and agreements with over 100 managed care plans covering over 125 million managed care lives.”

Mr. McDevitt continued, “The American Cancer Society estimates that there will be over 153,000 new cases of colorectal cancer in the U.S. in 2007. Given the impressive results of protocols involving continuous infusion therapy versus traditional bolus chemotherapy, these regimens are becoming a market standard for treatment of stage III and stage IV colorectal cancer. Currently, over 120 additional drug therapy clinical trials involving continuous infusion therapy are being conducted with similar results. As a result, InfuSystem has the opportunity to expand its current services to patients suffering from stage II colorectal cancer, as well as other forms of cancers, such as head and neck, pancreatic, gastric, lung, leukemia, and non-Hodgkin’s lymphoma, to name a few. We look forward to the upcoming shareholder vote to approve the acquisition of InfuSystem.”

**About InfuSystem, Inc.**

InfuSystem supplies external ambulatory infusion pumps allowing for the gradual administration of a drug over a period of days in the privacy of one’s home rather than higher dose treatments as in the case of chemotherapy administered in a hospital setting or doctor’s office.

**About HAPC, Inc.**

HAPC is a blank check company recently formed for the purpose of acquiring, through a merger, capital stock exchange, asset acquisition or other similar business combination, one or more operating businesses in the healthcare industry.

**Forward-Looking Statements**

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. These risks and uncertainties include general economic conditions, as well as other risks detailed from time to time in HAPC’s publicly filed documents.

---

**Additional Information and Where to Find It**

HAPC'S SHAREHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT BECAUSE IT CONTAINS IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents and other relevant documents filed by HAPC with the Securities and Exchange Commission (the "SEC") at the SEC's web site at [www.sec.gov](http://www.sec.gov).

*Contact:*

Investors:

Crescendo Communications, LLC

David K. Waldman/Klea K. Theoharis

212-671-1020